BFRI (Biofrontera) Tariff Resilience Score: 5/10 (As of Jun. 30, 2026)


BFRI Biofrontera Inc BFRI
44 GF Score
Price $1.02
GF Value $0.54
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Biofrontera Tariff Resilience Score?

Biofrontera BFRI +4.08% 44 Tariff Resilience Score is 5 as of Jun. 30, 2026. GuruFocus rates BFRI with a GF Score™ of 44/100 and a GF Value™ of $0.54 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,028 Drug Manufacturers companies, Biofrontera ranks better than 84.63% on this metric.

Biofrontera has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Biofrontera has Pharmaceutical company with international supply chains. Vulnerable to tariffs on raw materials and finished products, but can partially mitigate through strategic partnerships and pricing adjustments.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Biofrontera might have Average Resilient.

Biofrontera  (NAS:BFRI) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Biofrontera Tariff Resilience Score Related Terms

BFRI vs BIOE, APUS, CABR: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biofrontera Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Biofrontera's Tariff Resilience Score falls into.


BFRI
44GF Score
Biofrontera Inc BFRI
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Biofrontera (BFRI) has a Tariff Resilience Score of 5 as of Jun. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Biofrontera ranks #158 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 15.4%.
Is Biofrontera's Tariff Resilience Score too high?
Biofrontera's current Tariff Resilience Score is 5. Based on the distribution chart, Biofrontera ranks #158 out of 1028 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biofrontera has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera's Tariff Resilience Score compare to BIOE and APUS?
According to the Drug Manufacturers industry distribution chart, Biofrontera ranks #158 out of 1028 companies for Tariff Resilience Score. This places Biofrontera in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Biofrontera's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera (BFRI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.54, compared to a current price of $1.02 — trading 88.9% above its estimated fair value. The current Tariff Resilience Score is 5. Biofrontera's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Biofrontera (BFRI), the current Tariff Resilience Score is 5 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofrontera (BFRI) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera stock appears to be overvalued. The current stock price of $1.02 is trading 88.9% above its estimated GF Value™ of $0.54. GuruFocus considers Biofrontera to be Significantly Overvalued.

Key valuation signals for BFRI:

  • Tariff Resilience Score: 5
  • GF Value™: $0.54 vs. price of $1.02 (88.9% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the BFRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera Business Description

Address 660 Main Street, 1st Floor, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
44GF Score

Get the complete analysis for BFRI

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.02
Price
$0.54
GF Value